2 studies prove Revlimid's efficacy as maintenance therapy

05/20/2010 | Reuters

The risk of multiple myeloma progression was reduced by more than 50% in stem cell transplant patients who received Celgene's Revlimid as maintenance therapy, two studies showed. One of the clinical trials also noted an 88% survival rate for Revlimid patients after three years, compared with 80% in the group that took a placebo.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ